

Mucosal Vaccine Approach Targeting Respiratory Pathogens: The Next Wave of Vaccines

Juliana Pawel*

Department of Biological Sciences and Technologies, University of Regensburg, Regensburg 93053, Germany

Introduction

The emergence of the COVID-19 pandemic brought to the forefront the importance of vaccination in controlling the spread of respiratory pathogens. Vaccines have historically been administered through injection, targeting the systemic immune response. However, mucosal vaccines, which are administered through the mucous membranes of the respiratory and gastrointestinal tracts, offer a promising alternative in the fight against respiratory pathogens. This article explores the concept of mucosal vaccines, their advantages, challenges, and their potential as the next wave of vaccines to combat respiratory infections. Mucosal vaccines differ from traditional injectable vaccines in their mode of administration and the immune responses they evoke. Instead of delivering antigens through a needle, mucosal vaccines are administered through the mucous membranes, which are the moist, protective linings of various body passages, including the respiratory and gastrointestinal tracts. By targeting these mucosal surfaces, these vaccines aim to induce local and systemic immunity.

Description

In the post-COVID-19 era, mucosal vaccines may prove to be a game-changer, offering novel ways to protect individuals and populations against respiratory pathogens. Mucosal vaccines targeting respiratory pathogens have gained considerable attention as a potential game-changer in the field of vaccination. In this discussion, we will delve into the advantages and challenges associated with these vaccines and explore their potential impact on public health. Mucosal vaccines offer the unique advantage of stimulating immune responses at the site of pathogen entry [1]. In the context of respiratory pathogens, this means that the immune system is primed to defend against the virus or bacteria in the respiratory tract itself. This local immunity can serve as a crucial first line of defense, preventing the infection from taking hold in the first place.

The absence of needles in mucosal vaccines can have a transformative effect on vaccination programs. The fear of needles, especially among children, can discourage individuals from getting vaccinated. Mucosal vaccines, which can be administered as nasal sprays or oral formulations, can potentially improve vaccine coverage and compliance. Mucosal vaccines can evoke a faster immune response compared to traditional injectable vaccines. By engaging the body's first line of defense directly, they can provide protection earlier, which is especially critical in the context of emerging respiratory diseases like COVID-19. Swift action can help contain outbreaks more effectively. The potential for reduced production costs is a significant advantage of mucosal vaccines. Since they often require less antigen material than injectable

vaccines, the manufacturing process can be more cost-effective. This cost-efficiency could result in more affordable vaccination programs, making them accessible to a wider population [2].

Mucosal vaccines are associated with fewer systemic side effects. Unlike injectable vaccines that circulate throughout the bloodstream, mucosal vaccines mainly act locally. This characteristic can lead to a reduction in vaccine-related discomfort and complications, enhancing overall vaccine safety. Developing efficient and safe delivery systems for mucosal vaccines is a significant challenge. The formulations need to be stable, bioavailable, and capable of targeting specific mucosal surfaces. This challenge is particularly relevant when addressing diverse mucosal surfaces in the respiratory and gastrointestinal tracts [3]. Mucosal surfaces differ in their properties and characteristics. The challenge lies in designing vaccines that can effectively target and elicit the desired immune response in specific mucosal regions. Tailoring vaccine formulations to different target sites adds complexity to the development process.

Ensuring the quality and safety of mucosal vaccines is paramount, as they directly contact the body's mucous membranes. Rigorous quality control measures are necessary to prevent potential adverse effects and ensure that mucosal vaccines meet the highest safety standards. Mucosal vaccination is a relatively novel approach compared to traditional vaccines with a long history of successful use. This means that more research and clinical trials are required to establish the efficacy and safety of mucosal vaccines. A robust body of evidence is essential to gain public trust and regulatory approval. The intranasal influenza vaccine, FluMist, stands out as a successful example of a mucosal vaccine. Administered through the nose, it stimulates mucosal immunity and has been approved for use in both children and adults [4].

The on-going COVID-19 pandemic has accelerated research into mucosal vaccines. Various companies and research institutions are exploring mucosal vaccine candidates for COVID-19. These vaccines aim to deliver SARS-CoV-2 antigens directly to the respiratory mucosa, potentially offering a more effective means of protection against the virus. Mucosal vaccines, administered through the respiratory and gastrointestinal tracts, offer a promising avenue for the prevention and control of respiratory pathogens. Their potential advantages, including local immunity, needle-free administration, and cost-effectiveness, make them an attractive option in the realm of vaccination. However, addressing the challenges, such as delivery systems and quality control, is vital to harness their full potential. As the world continues to grapple with both on-going and emerging respiratory threats, mucosal vaccines may emerge as a pivotal tool in public health.

With further research and development, alongside comprehensive clinical trials, mucosal vaccines could play a pivotal role in protecting individuals and populations against respiratory pathogens, ushering in a new era of global public health preparedness. In the post-COVID-19 landscape, mucosal vaccines could redefine the way we approach vaccination, offering innovative solutions for the prevention and management of respiratory infections. Their potential to increase vaccination coverage, reduce systemic side effects, and enhance the speed of response make them a promising avenue for the future of global health security [5].

Conclusion

Mucosal vaccines, administered through the respiratory and gastrointestinal tracts, represent the next wave of vaccines in the fight against

*Address for Correspondence: Juliana Pawel, Department of Biological Sciences and Technologies, University of Regensburg, Regensburg 93053, Germany, E-mail: pawel.jul28@acae.ge

Copyright: © 2023 Pawel J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01 September, 2023, Manuscript No. jbps-23-116723; Editor Assigned: 04 September, 2023, PreQC No. P-116723; Reviewed: 15 September, 2023, QC No. Q-116723; Revised: 20 September, 2023, Manuscript No. R-116723; Published: 27 September, DOI:10.37421/2952-8100.2023.6.439

respiratory pathogens. Their potential advantages, including local immunity, needle-free administration, and cost-effectiveness, make them an appealing option. However, they come with challenges related to delivery systems, quality control, and the need for more research. As the world faces ongoing and emerging respiratory threats, mucosal vaccines may hold the key to a more effective and convenient approach to vaccination. Continued research and development in this field, along with robust clinical trials, will be essential in unlocking the full potential of mucosal vaccines to combat infectious diseases, making them a significant player in the future of global public health.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Mistry, Priyal, Fatima Barmania, Juanita Mellet and Kimberly Peta, et al. "SARS-CoV-2 variants, vaccines, and host immunity." *Front Immunol* 12 (2021): 809244.
2. Miquel-Clopes, A., E.G. Bentley, J.P. Stewart and S.R. Carding, et al. "Mucosal vaccines and technology." *Clin Exp Immunol* 196 (2019): 205–214.
3. Gao, Jiaxuan. "Vaccination with CanSinoBIO's inhaled COVID-19 vaccine has begun in China." *J. Biosaf Biosecur* 4 (2022): 163.
4. Sunagar, Raju, Sai D. Prasad, Raches Ella and Krishna Mohan Vadrevu, et al. "Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)." *Front Immunol* 13 (2022): 1063679.
5. Hassan, Ahmed O., Friederike Feldmann, Haiyan Zhao and David T. Curiel, et al. "A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques." *Cell Rep Med* 2 (2021): 100230.

How to cite this article: Pawel, Juliana. "Mucosal Vaccine Approach Targeting Respiratory Pathogens: The Next Wave of Vaccines." *J Biomed Pharma Sci* 6 (2023): 439.